Overview

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and safety of dose-dense(biweekly) carboplatin and paclitaxel ± trastuzumab as neoadjuvant treatment in early breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Guangdong General Hospital
Guangdong Provincial People's Hospital

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Trastuzumab